A Phase 3 interventional study of Treatment Period(JW0201) and Treatment Period(Placebo) in Type 2 Diabetes Mellitus, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2203
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 200 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
Drug: Treatment Period(JW0201) · Drug: Extension Period(JW0201)
Treatment period for 24 weeks (After the treatment period, take JW0201+C2202+C2203 for 28 weeks)
Drug: Treatment Period(Placebo) · Drug: Extension Period(JW0201)
JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
Also known as: JW0201+C2022+C2203
C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
Also known as: C2022+C2203
JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
Also known as: JW0201+C2022+C2203
HbA1c (24 Weeks) lowering effect
change in HbA1c
Time frame: 24 Weeks
HbA1c lowering effect
change in HbA1c
Time frame: 6, 12, 18, 32, 40, 52 Weeks
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical